Docetaxel

Name: Docetaxel
Brand: Selleck Chemicals
SKU: S1148
Rating: 5 (101 reviews)

For research use only.

Catalog No.S1148 Synonyms: RP56976, NSC 628503

101 publications

CAS No. 114977-28-5

Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Selleck's Docetaxel has been cited by 101 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(5):1200-1215

PubMed: 30100187 ( click the link to review the publication )

Mol Med Rep, 2021, 23(1)40

PubMed: 33179075 ( click the link to review the publication )

Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(2)e000807

PubMed: 33115941 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1168-9

PubMed: 31992853 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3784

PubMed: 33334024 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01091-1

PubMed: 33024272 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947623 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(1):39-51

PubMed: 31582531 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):364-374

PubMed: 31712394 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):249-262

PubMed: 32064165 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3302-3315

PubMed: 33163271 ( click the link to review the publication )

Oncogenesis, 2020, 7;9(5):45

PubMed: 32382014 ( click the link to review the publication )

Front Oncol, 2020, 1.4125

PubMed: 31998647 ( click the link to review the publication )

Front Oncol, 2020, 10:524922

PubMed: 33194583 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9034

PubMed: 33261142 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(7):1121-1134

PubMed: 32174789 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )
Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Pharmaceutics, 2020, 30;12(5) pii: E413

PubMed: 32366029 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):577

PubMed: 32709853 ( click the link to review the publication )

Cancer Lett, 2020, 470:95-105

PubMed: 31644929 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0206

PubMed: 31113844 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Cancer Res, 2019, canres.0656.2019

PubMed: 31694904 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3367-3380

PubMed: 31553907 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0473-8

PubMed: 31857702 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1970-1981

PubMed: 30807643 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 31018595 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Cell Death Discov, 2019, 0.30486111111

PubMed: 31583122 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):660

PubMed: 31506430 ( click the link to review the publication )

Arch Toxicol, 2019, 93(4):953-964

PubMed: 30863990 ( click the link to review the publication )

Cells, 2019, 9(1)

PubMed: 31877673 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):2115-2125

PubMed: 31266816 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17380

PubMed: 31758030 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19384

PubMed: 31852908 ( click the link to review the publication )
Sci Rep, 2019, 9(1):16647

PubMed: 31719636 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Clin Exp Metastasis, 2019, 36(2):97-108

PubMed: 30810874 ( click the link to review the publication )

Prostate, 2019, 79(11):1304-1315

PubMed: 31212367 ( click the link to review the publication )

Prostate, 2019, 79(9):1018-1031

PubMed: 31018021 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(3):551-559

PubMed: 30474758 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2764

PubMed: 31823522 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9899-9913

PubMed: 31819487 ( click the link to review the publication )

J Org Chem, 2019, 10.1021/acs.joc.9b02414

PubMed: 31858795 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6421-6432

PubMed: 30087142 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29752436 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14672

PubMed: 30279484 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Biomed Pharmacother, 2018, 99:445-450

PubMed: 29665645 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1901-1909

PubMed: 29393407 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Gene, 2018, 658:152-158

PubMed: 29518547 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(4):675-686

PubMed: 29460131 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26884-26899

PubMed: 29928491 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30773-30786

PubMed: 30112106 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560108 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Cancer Res, 2017, 77(12):3268-3279

PubMed: 28400477 ( click the link to review the publication )

Oncogene, 2017, 36(14):1991-2001

PubMed: 27721412 ( click the link to review the publication )

Oncogene, 2017, 36(11):1573-1584

PubMed: 27617580 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):660-669

PubMed: 28209757 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Breast Cancer Res Treat, 2017, 165(3):531-543

PubMed: 28695300 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Oncotarget, 2017, 9(4):4886-4896

PubMed: 29435149 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Prostate Cancer Prostatic Dis, 2016, 19(4):349-357

PubMed: 27349498 ( click the link to review the publication )

Int J Cancer, 2015, 136(9):2065-77

PubMed: 25274482 ( click the link to review the publication )

Int J Cancer, 2015, 136(9):2065-77

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:59

PubMed: 25902869 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23358-71

PubMed: 26160840 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )

Oncogenesis, 2014, 3:e100

PubMed: 24752235 ( click the link to review the publication )
Mol Pharm, 2014, 11(7):2040-50

PubMed: 24779589 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(5):811-23

PubMed: 24628949 ( click the link to review the publication )

Cell Cycle, 2014, 13(20):3292-301

PubMed: 25485509 ( click the link to review the publication )

J Nucl Med, 2013, 54(6):913-21

PubMed: 23564760 ( click the link to review the publication )

J Transl Med, 2013, 11:204

PubMed: 24004449 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Targets

Microtubules ^[1]
(Cell-free assay)

In vitro

Docetaxel is a cytotoxic agent, especially for proliferating cells, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by apoptosis of mitotically arrested cells or permanent mitotic block. Docetaxel suppresses microtubule dynamic instability as well as tread-milling, resulting in the failure of chromosomes to segregate to the daughter cells, which in turn triggers premature exit from mitosis rather than a block at this phase of the cell cycle. ^[2] Docetaxel inhibits the clonogenic survival of Human cancer cell Hs746T (stomach), AGS (stomach), HeLa (cervix), CaSki (cervix), BxPC3 (pancreas), Capan-1 (pancreas) with IC50 of 1 nM, 1 nM, 0.3 nM, 0.3 nM, 0.3 nM and 0.3 nM respectively. ^[4] Docetaxel inhibits endothelial cell migration that does not affects microtubule gross morphology or inhibit cell proliferation, although they does produce more subtle effects on microtubule dynamics. Docetaxel inhibits HUVEC migration with an observed IC50 of 1 pM. HUVEC chemotaxis stimulated by either of two angiogenic factors, thymidine phosphorylase or VEGF, is inhibited by Docetaxel with IC 50 of 10 pM and is ablated at 1 nM. ^[7] Docetaxel induces human monocytes, but not RAW 264.7 murine macrophages, Prostaglandin H Synthase-2m (PGHS-2) expression. ^[8]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HSC-3	M4HUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPZTWM2OD1yLkCwNFE{OiEQvF2=	MX\TRW5ITVJ?
5637	MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nhUGlEPTB;MD6wNFAyPDNizszN	NFjGfpFUSU6JRWK=
HT-144	NEf1e5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[3TWM2OD1yLkCwNFE2PyEQvF2=	NH3KR4JUSU6JRWK=
NCI-H292	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnqTWM2OD1yLkCwNFE2QSEQvF2=	MlS5V2FPT0WU
HCE-T	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXmU20xUUN3ME2wMlAxODF4MjFOwG0>	NW\IXIlXW0GQR1XS
ESS-1	NWDvZYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInib5VKSzVyPUCuNFAxOTd7IN88US=>	M{DZZ3NCVkeHUh?=
D-566MG	M1rNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMECwNVgzKM7:TR?=	NXjISXJPW0GQR1XS
CAL-62	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\NTWM2OD1yLkCwNFE5PSEQvF2=	NXHiRlRrW0GQR1XS
GT3TKB	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LoN2lEPTB;MD6wNFAzOzJizszN	NUHnXmZkW0GQR1XS
HSC-4	M1HI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjKZ3ZLUUN3ME2wMlAxODJ\|OTFOwG0>	NX3BXHNLW0GQR1XS
KOSC-2	NH\hVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jGOGlEPTB;MD6wNFAzPTVizszN	MmfoV2FPT0WU
NB14	M2PLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMECwNlYh\|ryP	MkC2V2FPT0WU
ES8	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPLTWM2OD1yLkCwNFI3KM7:TR?=	MX7TRW5ITVJ?
BFTC-905	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:ycVFKSzVyPUCuNFAxOjZ6IN88US=>	NY\5WXVpW0GQR1XS
A498	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPWTWM2OD1yLkCwNFI4QCEQvF2=	NFPDe2JUSU6JRWK=
HO-1-N-1	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTpTWM2OD1yLkCwNFI5OSEQvF2=	M3q0RXNCVkeHUh?=
SF539	M2LYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml2zTWM2OD1yLkCwNFMxOiEQvF2=	NFrXSGVUSU6JRWK=
HuO-3N1	M{HVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHq3VVZKSzVyPUCuNFAxOzB{IN88US=>	M2L3cXNCVkeHUh?=
NCI-H510A	M3:2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFW0dlFKSzVyPUCuNFAxOzN4IN88US=>	MkXVV2FPT0WU
CAL-27	M2G4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLHfWRKSzVyPUCuNFAxOzN7IN88US=>	MVzTRW5ITVJ?
TE-8	NIXMUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfWTWM2OD1yLkCwNFM3PiEQvF2=	M2PmV3NCVkeHUh?=
VA-ES-BJ	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMECwN\|c2KM7:TR?=	M2DGcXNCVkeHUh?=
RH-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHQTWM2OD1yLkCwNFM5PiEQvF2=	M2rsbXNCVkeHUh?=
COLO-800	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2WwNmlEPTB;MD6wNFA{QDhizszN	NVXGelBWW0GQR1XS
ES7	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvTTWM2OD1yLkCwNFM5QSEQvF2=	MoHkV2FPT0WU
GAMG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DWfmlEPTB;MD6wNFA1OTZizszN	M1;DSXNCVkeHUh?=
Ca9-22	NETXcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4K1NWlEPTB;MD6wNFA1OjNizszN	NUTmUVJyW0GQR1XS
SBC-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli2TWM2OD1yLkCwNFQ{KM7:TR?=	NYfPeJhiW0GQR1XS
RPMI-7951	M{eyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTIOZBKSzVyPUCuNFAxPDR6IN88US=>	MWTTRW5ITVJ?
SW1710	NV;WWW5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMECwOFY3KM7:TR?=	NFq5fGdUSU6JRWK=
HGC-27	NGfnUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMECwOFcyKM7:TR?=	M4TFTXNCVkeHUh?=
MC-IXC	NFvBRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ezWmlEPTB;MD6wNFA1PzlizszN	M1S3eXNCVkeHUh?=
FTC-133	M1\GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17IOGlEPTB;MD6wNFA1QDlizszN	NGS1PXFUSU6JRWK=
HT-1080	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj5dFFEUUN3ME2wMlAxODVyMTFOwG0>	MVfTRW5ITVJ?
NMC-G1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMECwOVE4KM7:TR?=	M{Hxe3NCVkeHUh?=
GI-1	NFLJSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rsSmlEPTB;MD6wNFA2OjhizszN	M2fqWXNCVkeHUh?=
CGTH-W-1	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXQTWM2OD1yLkCwNFU1OiEQvF2=	NH3lS4xUSU6JRWK=
A2058	NEHlNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXSb\|BKSzVyPUCuNFAxPTR2IN88US=>	NHq0RXZUSU6JRWK=
ETK-1	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTNXIY5UUN3ME2wMlAxODV3ODFOwG0>	MUPTRW5ITVJ?
NEC8	M2[zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfjeGRKSzVyPUCuNFAxPTZzIN88US=>	NEO3W21USU6JRWK=
TE-11	MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjITVFyUUN3ME2wMlAxODV4OTFOwG0>	NHfFcHNUSU6JRWK=
NCI-H720	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvZTWM2OD1yLkCwNFU5KM7:TR?=	NIXIWWVUSU6JRWK=
PSN1	NYixfZNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M36wXWlEPTB;MD6wNFA2QDFizszN	MnjYV2FPT0WU
SW780	M1H3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMECwOVg4KM7:TR?=	MkfUV2FPT0WU
8-MG-BA	Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPWdXZKSzVyPUCuNFAxPTh7IN88US=>	MYnTRW5ITVJ?
EC-GI-10	MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LLfWlEPTB;MD6wNFA2QTJizszN	MnfqV2FPT0WU
SJSA-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jXbWlEPTB;MD6wNFA3OTVizszN	M4LxdXNCVkeHUh?=
639-V	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMECwOlQ4KM7:TR?=	M{TE[3NCVkeHUh?=
PFSK-1	M4nSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMECwOlU4KM7:TR?=	NFWwZ4hUSU6JRWK=
DMS-273	M{XiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLTN3VMUUN3ME2wMlAxODZ5NDFOwG0>	NGT1dZFUSU6JRWK=
TE-9	NWnU[oFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PkUWlEPTB;MD6wNFA3PzZizszN	MlnrV2FPT0WU
SCC-25	NI[xXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXS3cYJ{UUN3ME2wMlAxODZ6IN88US=>	MoTTV2FPT0WU
PA-1	M4jNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMECwOlg4KM7:TR?=	NV\6O41bW0GQR1XS
MHH-ES-1	NGfSZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMECwO{DPxE1?	MkTxV2FPT0WU
Daoy	NXfQNmxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3jTWM2OD1yLkCwNFch\|ryP	NHjZZ4VUSU6JRWK=
G-402	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnK2TWM2OD1yLkCwNFcxPiEQvF2=	Ml30V2FPT0WU
YKG-1	M{HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFT0Om9KSzVyPUCuNFAxPzB5IN88US=>	NFTOZlJUSU6JRWK=
Ca-Ski	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjofmpsUUN3ME2wMlAxODd{ODFOwG0>	MmrvV2FPT0WU
CHP-212	M1jDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[wcGZKSzVyPUCuNFAxPzNizszN	Mn7mV2FPT0WU
SCC-4	M2Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr1V3U3UUN3ME2wMlAxODd\|OTFOwG0>	Mkm4V2FPT0WU
EW-3	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMECwO\|Q2KM7:TR?=	NG\vXpdUSU6JRWK=
P12-ICHIKAWA	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD5U3ZXUUN3ME2wMlAxODd2NTFOwG0>	MonCV2FPT0WU
HSC-2	M{TrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHCT3hKSzVyPUCuNFAxPzV3IN88US=>	MlPzV2FPT0WU
HN	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMECwO\|U5KM7:TR?=	NWK3NWVHW0GQR1XS
LXF-289	NG\hdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMECwO\|U5KM7:TR?=	NHjNNHVUSU6JRWK=
ES1	NHW0OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMECwO\|ch\|ryP	MmHJV2FPT0WU
NTERA-S-cl-D1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXuSFZKSzVyPUCuNFAxPzd\|IN88US=>	NIrEVXNUSU6JRWK=
K5	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jESmlEPTB;MD6wNFA4PzhizszN	MlTYV2FPT0WU
HOS	NGi0WHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jtRmlEPTB;MD6wNFA4QDJizszN	MYPTRW5ITVJ?
YH-13	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjNTWM2OD1yLkCwNFc6OSEQvF2=	MnfHV2FPT0WU
SW954	MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XDRWlEPTB;MD6wNFA5OjNizszN	MlW1V2FPT0WU
KYSE-510	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLxTWM2OD1yLkCwNFg1KM7:TR?=	NHLxXFRUSU6JRWK=
8505C	MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMECwPFU1KM7:TR?=	NWTYRnd3W0GQR1XS
A549	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7lTWM2OD1yLkCwNFg5OiEQvF2=	Moj2V2FPT0WU
Detroit562	M17HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED0fZRKSzVyPUCuNFAxQTB{IN88US=>	M{DZR3NCVkeHUh?=
ES5	NXi2WGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLiVFZVUUN3ME2wMlAxODlzIN88US=>	MnnsV2FPT0WU
KYSE-140	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDPSlJOUUN3ME2wMlAxODl\|MzFOwG0>	M4raO3NCVkeHUh?=
GMS-10	NHeze4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHqbllHUUN3ME2wMlAxODl2MTFOwG0>	NGS0RlZUSU6JRWK=
D-263MG	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPMWIxKSzVyPUCuNFAxQTR5IN88US=>	MmG4V2FPT0WU
BCPAP	NXnEfpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XwTmlEPTB;MD6wNFA6PDdizszN	NV7WfmtGW0GQR1XS
CHL-1	NIHtd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMECwPVU5KM7:TR?=	MXTTRW5ITVJ?
RKO	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfSTWM2OD1yLkCwNFk5QSEQvF2=	MVzTRW5ITVJ?
SW48	NHPFU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HPXmlEPTB;MD6wNFExOSEQvF2=	M1XoR3NCVkeHUh?=
BPH-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDub\|hKSzVyPUCuNFAyODJizszN	M4XER3NCVkeHUh?=
EFO-27	NWHVWno4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4iwUGlEPTB;MD6wNFExOiEQvF2=	Mn\2V2FPT0WU
CAL-33	M{\Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn2Wm9KSzVyPUCuNFAyODRizszN	NXi0NpN[W0GQR1XS
NCI-H1792	NU\sSnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn1TWM2OD1yLkCwNVA1KM7:TR?=	MlvsV2FPT0WU
BB30-HNC	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DQOGlEPTB;MD6wNFExPSEQvF2=	NVHNZpp5W0GQR1XS
VM-CUB-1	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMECxNFUh\|ryP	M{LpUnNCVkeHUh?=
TE-5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzLeJJbUUN3ME2wMlAxOTB4IN88US=>	NELR[nRUSU6JRWK=
NB13	MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX1TWM2OD1yLkCwNVA4KM7:TR?=	M{jOTHNCVkeHUh?=
NBsusSR	NIHpPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlm1TWM2OD1yLkCwNVEh\|ryP	M{Th[3NCVkeHUh?=
LNCaP-Clone-FGC	NUnDPVlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjOdWpKSzVyPUCuNFAyOSEQvF2=	M4PUdHNCVkeHUh?=
EPLC-272H	M2LheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkmzTWM2OD1yLkCwNVEyKM7:TR?=	MnPyV2FPT0WU
KNS-62	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMECxNVIh\|ryP	MYLTRW5ITVJ?
RERF-LC-MS	M4S2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXFNpJKSzVyPUCuNFAyOTNizszN	NInJ[lZUSU6JRWK=
LOXIMVI	M2i2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMECxNVYh\|ryP	MlW2V2FPT0WU
KINGS-1	M{nQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rEWWlEPTB;MD6wNFEyPyEQvF2=	NYrU[I41W0GQR1XS
T98G	M3;kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULHOohqUUN3ME2wMlAxOTF5IN88US=>	NFfmUpBUSU6JRWK=
HCC1806	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jBSWlEPTB;MD6wNFEyQCEQvF2=	NYTlOXU2W0GQR1XS
MZ1-PC	NFXDVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnW0TWM2OD1yLkCwNVE5KM7:TR?=	M1LVdHNCVkeHUh?=
RT-112	NXzteHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nsU2lEPTB;MD6wNFEyQSEQvF2=	MnvWV2FPT0WU
LK-2	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu3TWM2OD1yLkCwNVIyKM7:TR?=	M3n1O3NCVkeHUh?=
A375	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfpcmdKSzVyPUCuNFAyOjFizszN	NIP1b5dUSU6JRWK=
SF268	NW[we2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMECxNlEh\|ryP	NGix[4VUSU6JRWK=
H9	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjPTWM2OD1yLkCwNVI1KM7:TR?=	MoDyV2FPT0WU
KYSE-410	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LzR2lEPTB;MD6wNFEzPCEQvF2=	MX7TRW5ITVJ?
G-401	NFnuZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPkNZZuUUN3ME2wMlAxOTJ5IN88US=>	MVvTRW5ITVJ?
SW982	M3TufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMECxNlch\|ryP	NFzoUlhUSU6JRWK=
D-423MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMECxN{DPxE1?	NXjFdVgxW0GQR1XS
CAMA-1	NE\vfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rDcWlEPTB;MD6wNFE{OSEQvF2=	MoPVV2FPT0WU
SCC-9	MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fjUWlEPTB;MD6wNFE{OiEQvF2=	Ml25V2FPT0WU
SAS	M17RXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoH4TWM2OD1yLkCwNVM1KM7:TR?=	MVfTRW5ITVJ?
KYSE-180	M2\iWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\V[VE6UUN3ME2wMlAxOTN3IN88US=>	MmH3V2FPT0WU
EW-16	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rFO2lEPTB;MD6wNFE{PSEQvF2=	MVPTRW5ITVJ?
HD-MY-Z	M3HtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFL1eFJKSzVyPUCuNFAyPDFizszN	MVnTRW5ITVJ?
KYSE-450	M3;0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXWR\|hkUUN3ME2wMlAxOTR\|IN88US=>	MWXTRW5ITVJ?
LCLC-97TM1	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr2TXFKSzVyPUCuNFAyPDRizszN	M4PaTnNCVkeHUh?=
KS-1	M4P4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj5TWM2OD1yLkCwNVQ1KM7:TR?=	NEXPU3BUSU6JRWK=
TI-73	NYL0fZJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{KwbWlEPTB;MD6wNFE1PCEQvF2=	Ml62V2FPT0WU
A427	NUH1N3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PybmlEPTB;MD6wNFE1QCEQvF2=	MkXKV2FPT0WU
LB831-BLC	M1Hxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXRTWM2OD1yLkCwNVQ5KM7:TR?=	M3y0OHNCVkeHUh?=
MG-63	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHWTWM2OD1yLkCwNVUyKM7:TR?=	MVnTRW5ITVJ?
PANC-03-27	MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmmzTWM2OD1yLkCwNVU1KM7:TR?=	NFnn[VJUSU6JRWK=
23132-87	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLjTWM2OD1yLkCwNVU2KM7:TR?=	NYjYTHlkW0GQR1XS
ES4	NFm3RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7MUlRKSzVyPUCuNFAyPTVizszN	MV3TRW5ITVJ?
KP-4	NVvMZlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjscW1KSzVyPUCuNFAyPTZizszN	NXu2em1{W0GQR1XS
NCI-H1703	NIrkfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMECxOVch\|ryP	NEjvRllUSU6JRWK=
MCF7	NH7DU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYG1V5RDUUN3ME2wMlAxOTZzIN88US=>	NYn2R4J7W0GQR1XS
A172	M3v5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPGTWM2OD1yLkCwNVY{KM7:TR?=	MonuV2FPT0WU
CAL-39	M3zveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XSVGlEPTB;MD6wNFE3OyEQvF2=	NXW2fY5MW0GQR1XS
Saos-2	NEOzZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33MdmlEPTB;MD6wNFE3QCEQvF2=	MlLuV2FPT0WU
EW-11	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMECxOlkh\|ryP	MlXRV2FPT0WU
D-336MG	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HIbWlEPTB;MD6wNFE3QSEQvF2=	NFLZbGVUSU6JRWK=
SW13	M1TIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIj3Z3VKSzVyPUCuNFAyPjlizszN	Mki1V2FPT0WU
ME-180	M2jGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHiTWM2OD1yLkCwNVY6KM7:TR?=	NVXJOlVyW0GQR1XS
SK-MEL-2	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMECxO{DPxE1?	NWLQVYlQW0GQR1XS
697	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XwSWlEPTB;MD6wNFE4OiEQvF2=	MnvJV2FPT0WU
D-247MG	NEDhRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\HTWM2OD1yLkCwNVc{KM7:TR?=	MVXTRW5ITVJ?
EoL-1-cell	M{XFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\zTWM2OD1yLkCwNVc{KM7:TR?=	MUDTRW5ITVJ?
MV-4-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[4RVJKSzVyPUCuNFAyPzRizszN	NHzDcXJUSU6JRWK=
U-2-OS	NWTk[YdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMECxO\|Uh\|ryP	M2DWSnNCVkeHUh?=
NCI-H526	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HaXWlEPTB;MD6wNFE4PiEQvF2=	NF3iUm5USU6JRWK=
SK-NEP-1	NYPZVmR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMECxO\|Yh\|ryP	NUjuT5h7W0GQR1XS
DB	NUHHV49VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PndmlEPTB;MD6wNFE4QCEQvF2=	M4rwXHNCVkeHUh?=
GCT	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMECxPEDPxE1?	MoH5V2FPT0WU
HCT-116	NWq5TlA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W0[GlEPTB;MD6wNFE5OSEQvF2=	M3Tsc3NCVkeHUh?=
AU565	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4r4W2lEPTB;MD6wNFE5OSEQvF2=	MUTTRW5ITVJ?
KALS-1	M{\kPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoH4TWM2OD1yLkCwNVgyKM7:TR?=	MULTRW5ITVJ?
C2BBe1	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljsTWM2OD1yLkCwNVgzKM7:TR?=	MWnTRW5ITVJ?
Becker	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1njb2lEPTB;MD6wNFE5OyEQvF2=	M{G0WXNCVkeHUh?=
647-V	M4HjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMECxPFQh\|ryP	MX3TRW5ITVJ?
NCI-H2122	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMECxPFQh\|ryP	NFzPfJlUSU6JRWK=
SBC-5	NUPLVpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnNS2hKSzVyPUCuNFAyQDdizszN	M2jnSXNCVkeHUh?=
NB17	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\xfGlEPTB;MD6wNFE5QSEQvF2=	NHHz[odUSU6JRWK=
MHH-PREB-1	NIjzRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjQPHlKSzVyPUCuNFAyQDlizszN	NUHwWZc2W0GQR1XS
M14	NHvXWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXu3XlhDUUN3ME2wMlAxOTlzIN88US=>	M1LFdnNCVkeHUh?=
NCI-H1048	Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;2emxDUUN3ME2wMlAxOTl{IN88US=>	M3nWfnNCVkeHUh?=
CTB-1	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfDU5ZKSzVyPUCuNFAyQTJizszN	M3vxZXNCVkeHUh?=
SK-PN-DW	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jtTmlEPTB;MD6wNFE6PCEQvF2=	NWXTcVBVW0GQR1XS
H4	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fjSWlEPTB;MD6wNFE6PiEQvF2=	NFXRboZUSU6JRWK=
NCI-SNU-1	M2nDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMECxPVch\|ryP	MmXSV2FPT0WU
M059J	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4L6e2lEPTB;MD6wNFE6QCEQvF2=	NVnzN3BZW0GQR1XS
OVCAR-5	NGTmdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXn[JJkUUN3ME2wMlAxOTl7IN88US=>	M3vDPXNCVkeHUh?=
SK-MEL-28	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMECyNFMh\|ryP	MYXTRW5ITVJ?
PC-14	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nZOmlEPTB;MD6wNFIxQSEQvF2=	NYWzXHdjW0GQR1XS
OVCAR-8	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC1TWM2OD1yLkCwNlEzKM7:TR?=	NIHqO21USU6JRWK=
BB49-HNC	NFLqelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fvc2lEPTB;MD6wNFIyOiEQvF2=	MnvFV2FPT0WU
EFM-19	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DYeGlEPTB;MD6wNFIyPSEQvF2=	M{nM[nNCVkeHUh?=
BHY	NWXtNotVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC1TWM2OD1yLkCwNlE3KM7:TR?=	NVTBNm5lW0GQR1XS
SW756	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMECyNVYh\|ryP	MnLzV2FPT0WU
TE-1	NH6zXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHRfGRnUUN3ME2wMlAxOjF4IN88US=>	MVPTRW5ITVJ?
NCI-H2452	M4DWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\KTWM2OD1yLkCwNlE3KM7:TR?=	MYXTRW5ITVJ?
NCI-H1581	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMECyNVch\|ryP	MoP6V2FPT0WU
COR-L23	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMECyNkDPxE1?	Mmm0V2FPT0WU
RXF393	M1ewemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGn3cGtKSzVyPUCuNFAzOjJizszN	NFTxSWZUSU6JRWK=
BFTC-909	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rqemlEPTB;MD6wNFIzPSEQvF2=	M{HlXnNCVkeHUh?=
IST-MEL1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMECyNlUh\|ryP	MnT4V2FPT0WU
NCI-H650	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn2N\|FqUUN3ME2wMlAxOjJ3IN88US=>	MnTiV2FPT0WU
SK-UT-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMECyNlYh\|ryP	MlPPV2FPT0WU
GOTO	NWjkSIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37KfmlEPTB;MD6wNFIzPyEQvF2=	MY\TRW5ITVJ?
TYK-nu	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HkfGlEPTB;MD6wNFI{OiEQvF2=	M1vE[nNCVkeHUh?=
JVM-3	NY\hXWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMECyN\|Mh\|ryP	M4DDbHNCVkeHUh?=
SK-MES-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMECyN\|Mh\|ryP	NUDEUWduW0GQR1XS
SK-HEP-1	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjCfmZKSzVyPUCuNFAzOzRizszN	NHfJTXpUSU6JRWK=
J-RT3-T3-5	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7pTWM2OD1yLkCwNlM2KM7:TR?=	NUjzU3dpW0GQR1XS
A673	M2KwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXWTWM2OD1yLkCwNlM2KM7:TR?=	NXTEfoF3W0GQR1XS
NCI-H446	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHH5U25KSzVyPUCuNFAzPDNizszN	M37HVHNCVkeHUh?=
RPMI-2650	NG\WPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMECyOFYh\|ryP	MojqV2FPT0WU
HCE-4	M3S1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\sTWM2OD1yLkCwNlQ4KM7:TR?=	NWXXW5ZqW0GQR1XS
KGN	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzhV3BKSzVyPUCuNFAzPDdizszN	MnjBV2FPT0WU
U251	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIizb2FKSzVyPUCuNFAzPSEQvF2=	MVPTRW5ITVJ?
BxPC-3	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nZTWlEPTB;MD6wNFI2OSEQvF2=	NWnnR5hjW0GQR1XS
VMRC-RCZ	NIm4UnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfobm9KSzVyPUCuNFAzPTJizszN	MWDTRW5ITVJ?
TE-10	M3XIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULIXG9mUUN3ME2wMlAxOjV2IN88US=>	MWnTRW5ITVJ?
OC-314	NEX1T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfke2tiUUN3ME2wMlAxOjV4IN88US=>	NGS4dZJUSU6JRWK=
NCI-H1437	Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDETWM2OD1yLkCwNlYh\|ryP	M4jydXNCVkeHUh?=
SNU-387	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[2fVhsUUN3ME2wMlAxOjZzIN88US=>	NGrjdmNUSU6JRWK=
A388	NH;UZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXOwVm95UUN3ME2wMlAxOjZ3IN88US=>	M{W0dnNCVkeHUh?=
C-33-A	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMECyOlYh\|ryP	NUfUfVhjW0GQR1XS
CAL-51	M1qyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGT5epdKSzVyPUCuNFAzPzFizszN	M4DScXNCVkeHUh?=
Hs-578-T	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHK3Oo9KSzVyPUCuNFAzPzJizszN	NXmzTHg2W0GQR1XS
MDA-MB-415	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:xTWM2OD1yLkCwNlc1KM7:TR?=	Mnq0V2FPT0WU
SW1417	NYe1cnlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfYenpKSzVyPUCuNFAzPzZizszN	NWexSFdoW0GQR1XS
HCC70	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGX4V2dKSzVyPUCuNFAzPzdizszN	MojuV2FPT0WU
ES3	NUGwV2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\wV2lEPTB;MD6wNFI4PyEQvF2=	M3S3OXNCVkeHUh?=
KYSE-270	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HXXWlEPTB;MD6wNFI4QCEQvF2=	Mk\zV2FPT0WU
HT-29	NIHZO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvWTWM2OD1yLkCwNlgh\|ryP	NGjId3ZUSU6JRWK=
MDA-MB-361	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TmT2lEPTB;MD6wNFI5OSEQvF2=	MoDzV2FPT0WU
RPMI-8866	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\CVGlEPTB;MD6wNFI5OSEQvF2=	M2rLS3NCVkeHUh?=
JEG-3	NVPLcY45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHQTWM2OD1yLkCwNlgzKM7:TR?=	NXTqZlFPW0GQR1XS
HT-3	M2[2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMECyPFIh\|ryP	MWDTRW5ITVJ?
HTC-C3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMECyPFUh\|ryP	NEW5bZNUSU6JRWK=
NCI-H209	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfjTWM2OD1yLkCwNlg3KM7:TR?=	NELG[pRUSU6JRWK=
SKG-IIIa	NWPo[VFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMECyPFYh\|ryP	NFjhfFJUSU6JRWK=
SW962	NX\NUVJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMECyPVMh\|ryP	M3uw[XNCVkeHUh?=
LCLC-103H	NELLfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMECyPVMh\|ryP	Mk\nV2FPT0WU
DOK	NEP3VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfJVJdKSzVyPUCuNFAzQTRizszN	NEjVOGZUSU6JRWK=
SW1088	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfGbZFKSzVyPUCuNFAzQTVizszN	NGf1XnRUSU6JRWK=
GP5d	NIruVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPDTWM2OD1yLkCwNlk3KM7:TR?=	M2T4[HNCVkeHUh?=
EW-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUC4NFRUUUN3ME2wMlAxOjl6IN88US=>	MXfTRW5ITVJ?
CP66-MEL	M3XNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4K4NGlEPTB;MD6wNFMh\|ryP	MnHnV2FPT0WU
DEL	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHIUWNKSzVyPUCuNFA{ODFizszN	MknkV2FPT0WU
DU-4475	MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LZdWlEPTB;MD6wNFMxOiEQvF2=	NYX3bnZXW0GQR1XS
HEC-1	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXrUopKSzVyPUCuNFA{ODNizszN	Ml[3V2FPT0WU
U031	NHjJPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfLSmpGUUN3ME2wMlAxOzB5IN88US=>	MXHTRW5ITVJ?
BB65-RCC	M4K2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[2WmlEPTB;MD6wNFMxQCEQvF2=	NGT5OlNUSU6JRWK=
NUGC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMECzNFgh\|ryP	MojiV2FPT0WU
IST-SL1	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMECzNVIh\|ryP	Mn;zV2FPT0WU
LS-411N	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPoTWM2OD1yLkCwN\|E1KM7:TR?=	MWLTRW5ITVJ?
22RV1	NHvk[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMECzNVUh\|ryP	MX7TRW5ITVJ?
MKN28	NVzsUoZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofWTWM2OD1yLkCwN\|E4KM7:TR?=	M2n2Z3NCVkeHUh?=
ONS-76	NGXYcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XCS2lEPTB;MD6wNFMzOiEQvF2=	MmDTV2FPT0WU
SH-4	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLkdHBKSzVyPUCuNFA{OjJizszN	MWjTRW5ITVJ?
MIA-PaCa-2	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPpTWM2OD1yLkCwN\|I1KM7:TR?=	M1HkXnNCVkeHUh?=
CaR-1	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDD[W9KSzVyPUCuNFA{OjdizszN	M3W5V3NCVkeHUh?=
AGS	NVXJOmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorJTWM2OD1yLkCwN\|I5KM7:TR?=	NWXiR\|BwW0GQR1XS
SF126	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP2S4d5UUN3ME2wMlAxOzJ7IN88US=>	MU\TRW5ITVJ?
UACC-62	NFjKWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3mTWM2OD1yLkCwN\|Mh\|ryP	MkDSV2FPT0WU
NCI-H28	NWe2fIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f5PWlEPTB;MD6wNFM{PCEQvF2=	Mki4V2FPT0WU
A2780	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:xTWM2OD1yLkCwN\|M2KM7:TR?=	NFntVHFUSU6JRWK=
CTV-1	M3jCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrLTWM2OD1yLkCwN\|M4KM7:TR?=	M1XDOHNCVkeHUh?=
LC-2-ad	NGrkOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\vWlBKSzVyPUCuNFA{PCEQvF2=	NFnQ[lVUSU6JRWK=
NCI-H1770	NETLOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7zXI9KSzVyPUCuNFA{PDJizszN	MlfOV2FPT0WU
HuO9	M{fldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFS1U5lKSzVyPUCuNFA{PDZizszN	NIDwWHpUSU6JRWK=
U-266	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjpOGRkUUN3ME2wMlAxOzR6IN88US=>	NGHy[5pUSU6JRWK=
MLMA	M1nNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXL6Wno4UUN3ME2wMlAxOzV3IN88US=>	M1:ydHNCVkeHUh?=
U-87-MG	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET1Z2pKSzVyPUCuNFA{PTVizszN	Ml7VV2FPT0WU
GI-ME-N	NGfLSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\5bW5IUUN3ME2wMlAxOzV6IN88US=>	NGXlOYFUSU6JRWK=
HL-60	NUGzXm1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS0TYcyUUN3ME2wMlAxOzV7IN88US=>	Ml\vV2FPT0WU
EGI-1	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zqXWlEPTB;MD6wNFM3OiEQvF2=	NWjjdJJDW0GQR1XS
NCI-H23	MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;yTWM2OD1yLkCwN\|Y1KM7:TR?=	M2D4T3NCVkeHUh?=
NCI-H226	M3vBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml63TWM2OD1yLkCwN\|Y5KM7:TR?=	MYDTRW5ITVJ?
NCI-H520	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL2WGRCUUN3ME2wMlAxOzd{IN88US=>	NViwfHU3W0GQR1XS
L-363	NUXUVox{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMECzO\|Yh\|ryP	M2fJe3NCVkeHUh?=
CAL-12T	NYS4[mNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmX5TWM2OD1yLkCwN\|c3KM7:TR?=	M136TXNCVkeHUh?=
BT-20	M1TwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjiS2FKSzVyPUCuNFA{PzZizszN	NHWzcFZUSU6JRWK=
SNB75	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XtWmlEPTB;MD6wNFM5OSEQvF2=	NXH2OIt{W0GQR1XS
A4-Fuk	M2PLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMECzPUDPxE1?	NIm1WmlUSU6JRWK=
BE-13	MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7kbFJKSzVyPUCuNFA{QTNizszN	MYnTRW5ITVJ?
NCI-H1395	M2H1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMECzPVYh\|ryP	MV3TRW5ITVJ?
SW620	NY\vZos2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPpTWM2OD1yLkCwN\|k4KM7:TR?=	NVnBZnVFW0GQR1XS
KNS-81-FD	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHaTWM2OD1yLkCwN\|k6KM7:TR?=	MUjTRW5ITVJ?
RD	M2DGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP2[WZKSzVyPUCuNFA1KM7:TR?=	M4W0fnNCVkeHUh?=
HLE	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\OVGlEPTB;MD6wNFQxPSEQvF2=	MmnIV2FPT0WU
OVCAR-3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i1fGlEPTB;MD6wNFQxPyEQvF2=	NVWxdnc3W0GQR1XS
KM12	M1rB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Dud2lEPTB;MD6wNFQxQCEQvF2=	NUjYWXJ1W0GQR1XS
HCC2998	M1\u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzlT\|ZKSzVyPUCuNFA1ODhizszN	NFHC[GFUSU6JRWK=
D-502MG	M{TXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMEC0NUDPxE1?	MXzTRW5ITVJ?
KNS-42	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEC0NVIh\|ryP	NUjabXVnW0GQR1XS
LS-123	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4L4[WlEPTB;MD6wNFQzPSEQvF2=	M3fDPXNCVkeHUh?=
SiHa	NXzROoZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nicGlEPTB;MD6wNFQ{KM7:TR?=	M3L0THNCVkeHUh?=
T47D	NIDwc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEC0N\|Eh\|ryP	NWLTUWhLW0GQR1XS
EW-24	NVXQOJhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvxRWdKSzVyPUCuNFA1OzNizszN	NIDsV3ZUSU6JRWK=
CAL-120	NYj0dYJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf2VpFKSzVyPUCuNFA1OzVizszN	MXTTRW5ITVJ?
JAR	M4naUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XqUGlEPTB;MD6wNFQ{PyEQvF2=	NYXEVlJrW0GQR1XS
QIMR-WIL	M1rnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEC0N\|gh\|ryP	NGK0d\|RUSU6JRWK=
OCUB-M	NXnRNYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS5TWM2OD1yLkCwOFM5KM7:TR?=	NGr1cW5USU6JRWK=
Calu-6	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEC0OFch\|ryP	NVvkUll2W0GQR1XS
MDA-MB-453	NF3JTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLWTWM2OD1yLkCwOFUyKM7:TR?=	NH\yeplUSU6JRWK=
MKN45	NFrMTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjOdFVwUUN3ME2wMlAxPDV\|IN88US=>	MVvTRW5ITVJ?
ECC10	NXvmPVh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULu[ZJkUUN3ME2wMlAxPDZizszN	MlnnV2FPT0WU
RVH-421	M1SyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlH2TWM2OD1yLkCwOFYyKM7:TR?=	MUPTRW5ITVJ?
TGBC11TKB	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXHTWM2OD1yLkCwOFY6KM7:TR?=	MojMV2FPT0WU
MOLT-4	NFHTU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrPbnpKSzVyPUCuNFA1PzFizszN	MorqV2FPT0WU
LN-405	NHLHeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLDTWM2OD1yLkCwOFgzKM7:TR?=	NILuRXdUSU6JRWK=
S-117	NVW0Sm1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLoTWM2OD1yLkCwOFg3KM7:TR?=	NXT3NHBnW0GQR1XS
RPMI-8226	MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLVTWM2OD1yLkCwOFk4KM7:TR?=	M2PieXNCVkeHUh?=
KYSE-150	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\ZOJdKSzVyPUCuNFA1QTlizszN	NVjjdVVMW0GQR1XS
NCI-H1666	M17NT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4[wcWlEPTB;MD6wNFUxPSEQvF2=	MmDwV2FPT0WU
Mewo	MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnNTWM2OD1yLkCwOVA2KM7:TR?=	M1PwXnNCVkeHUh?=
AN3-CA	NX;rfmNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEC1NFch\|ryP	NF\6VXpUSU6JRWK=
COLO-680N	NFrMTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mke1TWM2OD1yLkCwOVA5KM7:TR?=	MoCxV2FPT0WU
FADU	NV7DfJRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[w[ZRnUUN3ME2wMlAxPTFizszN	NHXFPJFUSU6JRWK=
GB-1	M17GN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;0SmlEPTB;MD6wNFUyOSEQvF2=	NFfmRWRUSU6JRWK=
KASUMI-1	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTBN2JuUUN3ME2wMlAxPTFzIN88US=>	MVjTRW5ITVJ?
NOMO-1	M1zhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T5[GlEPTB;MD6wNFUyOyEQvF2=	NVviWGtKW0GQR1XS
BV-173	M4TGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\QdmlEPTB;MD6wNFU{KM7:TR?=	NUHoN5l2W0GQR1XS
RO82-W-1	M4TaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHSWHp3UUN3ME2wMlAxPTNzIN88US=>	NFW1ZmpUSU6JRWK=
LB2241-RCC	NF[4fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L5WWlEPTB;MD6wNFU{OSEQvF2=	NGnUSIxUSU6JRWK=
NCI-H2170	M4HkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTYWnhKSzVyPUCuNFA2OzVizszN	MmTGV2FPT0WU
SK-N-AS	NV7UT4tKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qyZmlEPTB;MD6wNFU{PSEQvF2=	MXLTRW5ITVJ?
NCI-H1651	NHfXN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mli0TWM2OD1yLkCwOVQh\|ryP	MneyV2FPT0WU
NCI-SNU-5	NGCxbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7CTWM2OD1yLkCwOVQ2KM7:TR?=	NIXuUVhUSU6JRWK=
SN12C	M1rLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMEC1OUDPxE1?	MmTEV2FPT0WU
KY821	NWHoXnhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi1XZBKSzVyPUCuNFA2PTFizszN	MkTDV2FPT0WU
SW1573	NXnIPYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEC1OVQh\|ryP	Mm\zV2FPT0WU
OE19	NF3zdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEC1OVkh\|ryP	M3TwXHNCVkeHUh?=
MPP-89	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPMTFJKSzVyPUCuNFA2PjdizszN	NXTueIM4W0GQR1XS
HuCCT1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXpTWM2OD1yLkCwOVY5KM7:TR?=	NHu4ZpJUSU6JRWK=
SW1783	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Xx[WlEPTB;MD6wNFU4KM7:TR?=	MXjTRW5ITVJ?
8305C	NX3qeXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEC1O\|Yh\|ryP	MWTTRW5ITVJ?
OVCAR-4	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7CTWM2OD1yLkCwOVg3KM7:TR?=	M4G3V3NCVkeHUh?=
MMAC-SF	M1TDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjmUmJKSzVyPUCuNFA2QDZizszN	NGS5PIlUSU6JRWK=
COLO-824	NV\nfWE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrMTWM2OD1yLkCwOVkh\|ryP	NXfUc4VJW0GQR1XS
HCC38	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMEC2JO69VQ>?	NVPIRVBoW0GQR1XS
NCI-H1648	NEHsdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HuZ2lEPTB;MD6wNFYxOSEQvF2=	M1Pz[nNCVkeHUh?=
NCI-H1573	M4nkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIj5bHdKSzVyPUCuNFA3ODdizszN	NV3U[lFiW0GQR1XS
MFM-223	NWD3b4tET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPKeJZzUUN3ME2wMlAxPjF4IN88US=>	M2jNWXNCVkeHUh?=
NCI-H810	NInUSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\wS\|kyUUN3ME2wMlAxPjJ{IN88US=>	M4HFZXNCVkeHUh?=
EM-2	NUnvVlNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2CxfGlEPTB;MD6wNFYzOyEQvF2=	NXvG[opSW0GQR1XS
D-283MED	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMEC2NlQh\|ryP	MWLTRW5ITVJ?
NCI-H1755	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMEC2NlQh\|ryP	MY\TRW5ITVJ?
KYSE-70	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHJTWM2OD1yLkCwOlI1KM7:TR?=	NILvclVUSU6JRWK=
SW626	NVjhPWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMEC2NlQh\|ryP	MnfWV2FPT0WU
WM-115	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHS2eGVKSzVyPUCuNFA3OjdizszN	Mnv6V2FPT0WU
NB69	M{fXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMEC2Nlkh\|ryP	NWLkT4R4W0GQR1XS
DOHH-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzVdY5KSzVyPUCuNFA3OyEQvF2=	NETtbIJUSU6JRWK=
MEL-JUSO	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvITWM2OD1yLkCwOlM6KM7:TR?=	MWrTRW5ITVJ?
IGR-1	M{D1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr5TWM2OD1yLkCwOlQyKM7:TR?=	MX7TRW5ITVJ?
ACN	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTITWM2OD1yLkCwOlQ1KM7:TR?=	NEnic3pUSU6JRWK=
KARPAS-45	NH[wS\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEC2OVIh\|ryP	NFnyfY9USU6JRWK=
HC-1	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXywXYVFUUN3ME2wMlAxPjV4IN88US=>	MUDTRW5ITVJ?
MZ2-MEL	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWG0Sm5NUUN3ME2wMlAxPjV6IN88US=>	NX74OXVyW0GQR1XS
NCI-H1355	M{HVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMEC2O\|kh\|ryP	NVrIZmxCW0GQR1XS
HuP-T4	M{\SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\aTWM2OD1yLkCwOlc6KM7:TR?=	Mm\rV2FPT0WU
AsPC-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37n[mlEPTB;MD6wNFY5OyEQvF2=	MVLTRW5ITVJ?
SCC-15	NELzRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMEC2PFkh\|ryP	M4\VfnNCVkeHUh?=
CP50-MEL-B	NVvncWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLYTWM2OD1yLkCwOlk{KM7:TR?=	MlnHV2FPT0WU
DMS-114	M2jTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfVTWM2OD1yLkCwOlk3KM7:TR?=	NWXQW21lW0GQR1XS
KYSE-520	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEC3JO69VQ>?	MofiV2FPT0WU
NCI-H2228	MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TmO2lEPTB;MD6wNFczPSEQvF2=	MVHTRW5ITVJ?
COLO-829	MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGn6RWNKSzVyPUCuNFA4OjVizszN	M{PnVnNCVkeHUh?=
NCI-H2052	NF36TlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMEC3Nlch\|ryP	NUfGT2Z7W0GQR1XS
HOP-92	NFjhZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDk[odKSzVyPUCuNFA4OyEQvF2=	NYf3[XVqW0GQR1XS
MDA-MB-231	NFK0boFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzXUIJQUUN3ME2wMlAxPzNizszN	MnTtV2FPT0WU
SK-MEL-30	NEPuc\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jnTGlEPTB;MD6wNFc{OiEQvF2=	NV3UdVA5W0GQR1XS
NCI-H2087	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLo[lRKSzVyPUCuNFA4PDhizszN	MnuxV2FPT0WU
SW900	NV7UPZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\rUVdKSzVyPUCuNFA4PTVizszN	Ml7TV2FPT0WU
NCI-H358	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MneyTWM2OD1yLkCwO\|U5KM7:TR?=	M3e2WnNCVkeHUh?=
NCI-H2126	NYGz[oVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vGS2lEPTB;MD6wNFc4OyEQvF2=	NFfNfY5USU6JRWK=
TGBC24TKB	NXvGNY1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH2xWFVKSzVyPUCuNFA4QDFizszN	M1radHNCVkeHUh?=
786-0	NHPkclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjMTWtKSzVyPUCuNFA4QDZizszN	M4DQd3NCVkeHUh?=
no-10	MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK5[G9KSzVyPUCuNFA4QDhizszN	NEHyd3NUSU6JRWK=
SCH	M1S2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULxWHJDUUN3ME2wMlAxQDF6IN88US=>	NEnKdIdUSU6JRWK=
COLO-741	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDXTWM2OD1yLkCwPFIh\|ryP	NEjRbolUSU6JRWK=
NCI-H82	NUTMSGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrFbIp{UUN3ME2wMlAxQDJ{IN88US=>	M3rIenNCVkeHUh?=
MOLT-16	M4nISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEC4Nlch\|ryP	M3vEXXNCVkeHUh?=
IST-MES1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfHUIVKSzVyPUCuNFA5PCEQvF2=	NHfnW\|lUSU6JRWK=
NCI-H1623	NIjWZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXl[lVKSzVyPUCuNFA5PTZizszN	M2PJUnNCVkeHUh?=
NCI-H1299	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDjXldKSzVyPUCuNFA5PTdizszN	MkD1V2FPT0WU
SNU-423	NW\kRWZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HU[2lEPTB;MD6wNFg2PyEQvF2=	NFT3WWlUSU6JRWK=
ALL-PO	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEC4OkDPxE1?	NVnNRYZDW0GQR1XS
DK-MG	M1m1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDXTWM2OD1yLkCwPFYh\|ryP	MULTRW5ITVJ?
LB1047-RCC	NUe4NVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\PR2lEPTB;MD6wNFg5KM7:TR?=	MVPTRW5ITVJ?
OMC-1	NULRW4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMEC5NFYh\|ryP	NGjjU3hUSU6JRWK=
TGBC1TKB	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXiZolEUUN3ME2wMlAxQTFizszN	MVfTRW5ITVJ?
DBTRG-05MG	NFO0[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvZZ4Z5UUN3ME2wMlAxQTF5IN88US=>	NHnneldUSU6JRWK=
HPAF-II	NG\JUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHC[GpKSzVyPUCuNFA6OjZizszN	M2OwV3NCVkeHUh?=
A204	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofVTWM2OD1yLkCwPVM1KM7:TR?=	M4C2[HNCVkeHUh?=
TK10	NH\sZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7YdWZKSzVyPUCuNFA6PzdizszN	M17FOHNCVkeHUh?=
BHT-101	NXTkepRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXuTWM2OD1yLkCwPVgh\|ryP	MVHTRW5ITVJ?
SK-N-DZ	NW\Jb4w3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3u2WGlEPTB;MD6wNFk5OyEQvF2=	NHrye\|FUSU6JRWK=
ChaGo-K-1	NEL5ZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMEC5PFgh\|ryP	MlTzV2FPT0WU
NCI-H661	NYPr[4FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\2PWlEPTB;MD6wNVAxPSEQvF2=	NYizZmpFW0GQR1XS
AM-38	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTveJA{UUN3ME2wMlAyODJ2IN88US=>	MUTTRW5ITVJ?
ML-2	M{LrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7VfJFRUUN3ME2wMlAyODJ7IN88US=>	MUTTRW5ITVJ?
TCCSUP	M{HU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXITWM2OD1yLkCxNFM3KM7:TR?=	NFO5dGJUSU6JRWK=
SW1990	NGfu[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITK[4tKSzVyPUCuNFExPDdizszN	MkDkV2FPT0WU
HCC1395	NWTVS\|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ywUmlEPTB;MD6wNVA2PiEQvF2=	M{XCNnNCVkeHUh?=
PANC-10-05	NH\Ob\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMEGwOVYh\|ryP	MYfTRW5ITVJ?
CAKI-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn2TWM2OD1yLkCxNFc{KM7:TR?=	NUK5RWNOW0GQR1XS
HuP-T3	NGG2[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMEGwO\|ch\|ryP	MojvV2FPT0WU
HT-1197	NUjEPZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTBTWM2OD1yLkCxNFg1KM7:TR?=	NF;VNJhUSU6JRWK=
MOLT-13	NX7HeYpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTHTYVKSzVyPUCuNFExQDZizszN	MWjTRW5ITVJ?
NCI-H1563	NY\J[JJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYS5SIplUUN3ME2wMlAyODh5IN88US=>	NILO[4lUSU6JRWK=
NCI-N87	NUTGXpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DhXmlEPTB;MD6wNVA6OyEQvF2=	MonMV2FPT0WU
LB373-MEL-D	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXMXYZKSzVyPUCuNFExQTRizszN	MoraV2FPT0WU
EFO-21	NIi4OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEe4RldKSzVyPUCuNFEyKM7:TR?=	NFvxTm5USU6JRWK=
LU-134-A	M3ruUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLtR2lKSzVyPUCuNFEyODJizszN	M4TsSnNCVkeHUh?=
DU-145	MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHHTWM2OD1yLkCxNVA4KM7:TR?=	MnfsV2FPT0WU
SF295	NFf6[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEGxNlYh\|ryP	MYXTRW5ITVJ?
ABC-1	NHfrVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XLSGlEPTB;MD6wNVE1PiEQvF2=	NXHzWJhxW0GQR1XS
TE-6	NU\qVIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrUTWM2OD1yLkCxNVQ5KM7:TR?=	MkLQV2FPT0WU
GAK	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlewTWM2OD1yLkCxNVU5KM7:TR?=	MWjTRW5ITVJ?
LU-139	NYnqSGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEGxOlYh\|ryP	NVnhWml1W0GQR1XS
EW-18	Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7TT\|BKUUN3ME2wMlAyOTZ7IN88US=>	M{i3S3NCVkeHUh?=
MSTO-211H	M3POcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMEGxO\|Mh\|ryP	NVu1S\|NTW0GQR1XS
KU812	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzKTWM2OD1yLkCxNVk5KM7:TR?=	NXzJdJplW0GQR1XS
NCI-H441	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXPcXZKSzVyPUCuNFEyQThizszN	NUPC[pRVW0GQR1XS
LU-99A	MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGm3SVJKSzVyPUCuNFEzKM7:TR?=	NHXkRVBUSU6JRWK=
NB10	NU\6ZlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HsXWlEPTB;MD6wNVIxQSEQvF2=	M4XkTHNCVkeHUh?=
NCI-H1650	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TjXmlEPTB;MD6wNVIzQSEQvF2=	M{jZXHNCVkeHUh?=
YAPC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M164fmlEPTB;MD6wNVI{PyEQvF2=	NF7ycFhUSU6JRWK=
HT55	M2nsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PkNWlEPTB;MD6wNVI1OiEQvF2=	Mn;NV2FPT0WU
NB7	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoP0TWM2OD1yLkCxNlQ{KM7:TR?=	M2PXVnNCVkeHUh?=
NCI-H2030	Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHueoxKSzVyPUCuNFEzPTRizszN	M3XXfXNCVkeHUh?=
EW-22	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M134cGlEPTB;MD6wNVI2PiEQvF2=	MVXTRW5ITVJ?
UMC-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu3NZNKSzVyPUCuNFEzQDNizszN	MX3TRW5ITVJ?
MKN7	NEThbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXwbm9KSzVyPUCuNFEzQDNizszN	NF7SZYZUSU6JRWK=
OE33	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMEGzJO69VQ>?	M1;C[HNCVkeHUh?=
SK-LU-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEGzNlQh\|ryP	NW\GR\|FtW0GQR1XS
LAMA-84	M3P3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVqyeYJWUUN3ME2wMlAyOzJ6IN88US=>	NGX2bpdUSU6JRWK=
IA-LM	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnNPG5KSzVyPUCuNFE{OyEQvF2=	M4XvOXNCVkeHUh?=
HuH-7	NIi3d5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTwZ4MxUUN3ME2wMlAyOzV2IN88US=>	NH;pXolUSU6JRWK=
J82	NXW2cHplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3q1UGlEPTB;MD6wNVM6KM7:TR?=	MWPTRW5ITVJ?
CFPAC-1	NFnteG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDrTWM2OD1yLkCxOFA3KM7:TR?=	MUHTRW5ITVJ?
MN-60	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWntbII3UUN3ME2wMlAyPDJ7IN88US=>	NYKze3h3W0GQR1XS
A704	M4XXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3UVnE2UUN3ME2wMlAyPDN6IN88US=>	MVzTRW5ITVJ?
SW684	Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mom0TWM2OD1yLkCxOFUzKM7:TR?=	MlK3V2FPT0WU
NOS-1	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnaOIlKSzVyPUCuNFE1PiEQvF2=	NVXqfZd5W0GQR1XS
U-118-MG	NInQXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr2OJpKSzVyPUCuNFE1PyEQvF2=	NH70OJZUSU6JRWK=
NCI-H596	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMEG0O\|ch\|ryP	MXvTRW5ITVJ?
RS4-11	NUjsUGU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTjb3NKSzVyPUCuNFE2OTZizszN	NVi3elVwW0GQR1XS
KP-N-YS	M3vBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ewNmlEPTB;MD6wNVUzOyEQvF2=	MXHTRW5ITVJ?
MS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDCTWM2OD1yLkCxOVQ2KM7:TR?=	MUXTRW5ITVJ?
A101D	NHTmV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfkT5BZUUN3ME2wMlAyPTR7IN88US=>	MnPRV2FPT0WU
DSH1	M2HRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\XTWM2OD1yLkCxOkDPxE1?	Mk\4V2FPT0WU
CAS-1	M{TVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HQc2lEPTB;MD6wNVYxQSEQvF2=	MnO3V2FPT0WU
NCI-H2347	NYLXOXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLsTWM2OD1yLkCxOlM3KM7:TR?=	MnvxV2FPT0WU
T-24	M3zBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTTTWM2OD1yLkCxO\|A2KM7:TR?=	MnvXV2FPT0WU
MEG-01	NEjzfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O1UWlEPTB;MD6wNVc{PyEQvF2=	NGjkRZpUSU6JRWK=
NCI-H2291	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\mZpR2UUN3ME2wMlAyQDN6IN88US=>	M{jBfXNCVkeHUh?=
SW872	MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\sTWM2OD1yLkCxPFY4KM7:TR?=	MkLyV2FPT0WU
no-11	M3HtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEG4PFch\|ryP	NF7jTWdUSU6JRWK=
NB5	M2XKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL0S2JKSzVyPUCuNFE5QTFizszN	MoXNV2FPT0WU
MZ7-mel	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPYTWM2OD1yLkCxPVM1KM7:TR?=	NF7FUmVUSU6JRWK=
BT-474	NWmxO45YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULMOmRGUUN3ME2wMlAyQTR\|IN88US=>	MnXtV2FPT0WU
OAW-28	NHHXTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEG5OVYh\|ryP	M4HsUnNCVkeHUh?=
ES6	NY\LWGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMEKwNFgh\|ryP	Ml;CV2FPT0WU
PC-3	M3nnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[wTWM2OD1yLkCyNFM3KM7:TR?=	M4jpbHNCVkeHUh?=
COR-L88	MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEKwOVQh\|ryP	MWXTRW5ITVJ?
D-392MG	NUfpeW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[2TWM2OD1yLkCyNFY5KM7:TR?=	M{nyWnNCVkeHUh?=
LB2518-MEL	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFexflFKSzVyPUCuNFIyPjFizszN	M{fBOnNCVkeHUh?=
LoVo	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF76WZpKSzVyPUCuNFIyPzJizszN	Ml;wV2FPT0WU
HCC1954	NXf4N3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMEKxPVIh\|ryP	Mlm1V2FPT0WU
COLO-792	NVS0W4lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlywTWM2OD1yLkCyNVk3KM7:TR?=	M{PQS3NCVkeHUh?=
KLE	M3nMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEKzNlMh\|ryP	MUjTRW5ITVJ?
MDA-MB-157	M3;UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHP4NVhKSzVyPUCuNFI{PDlizszN	MU\TRW5ITVJ?
PANC-08-13	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMEK0OlUh\|ryP	NVjE[2JqW0GQR1XS
NCI-H727	M{PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMEK0O\|Qh\|ryP	MV3TRW5ITVJ?
NCI-H1155	NG\LUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:4[ZhKSzVyPUCuNFI1PzdizszN	NH3uWYdUSU6JRWK=
GCIY	NIrDephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMEK1NFIh\|ryP	NUDvXWRSW0GQR1XS
MKN1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn2wTWM2OD1yLkCyOVc3KM7:TR?=	NYXBcGlvW0GQR1XS
NCI-H1092	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{izV2lEPTB;MD6wNlY2PCEQvF2=	NGPpXVFUSU6JRWK=
RMG-I	NYTvcm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DKUWlEPTB;MD6wNlch\|ryP	M4HBRnNCVkeHUh?=
NB12	M3y3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zFPWlEPTB;MD6wNlczKM7:TR?=	M{fXNXNCVkeHUh?=
RCM-1	M1Pz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMEK4NVkh\|ryP	NX7qUYRlW0GQR1XS
C3A	NFfHNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml24TWM2OD1yLkCyPFIzKM7:TR?=	Moe0V2FPT0WU
NCI-H747	NWDPcZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XmPWlEPTB;MD6wNlg{PyEQvF2=	NULkZXlHW0GQR1XS
LB771-HNC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnBT4ROUUN3ME2wMlAzQDN5IN88US=>	MWPTRW5ITVJ?
EW-13	NX7HfWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjsdJNKSzVyPUCuNFI6ODRizszN	MnrXV2FPT0WU
CAL-72	NW\ybmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEK5NVgh\|ryP	MWHTRW5ITVJ?
HH	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rMNmlEPTB;MD6wNlk6QCEQvF2=	NWDicVB3W0GQR1XS
UACC-257	NXzyWHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXFRWlKSzVyPUCuNFMxOyEQvF2=	NIjYZXJUSU6JRWK=
OAW-42	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPCbVVSUUN3ME2wMlA{ODNizszN	MkO1V2FPT0WU
CAPAN-1	NYDDfXlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMEOwOVIh\|ryP	MUfTRW5ITVJ?
SNU-C2B	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEOwOlMh\|ryP	MlG4V2FPT0WU
NKM-1	NVjoWnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY[4Row2UUN3ME2wMlA{OTZ7IN88US=>	M1Tq[3NCVkeHUh?=
GR-ST	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEOxPFUh\|ryP	MWHTRW5ITVJ?
SW1463	M1fKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDNUHNCUUN3ME2wMlA{OzN5IN88US=>	MV7TRW5ITVJ?
MEL-HO	NUH1XndOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH6zVIlKSzVyPUCuNFM1OjFizszN	NUO3OHh2W0GQR1XS
NCI-H2342	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHrVZNKSzVyPUCuNFM3OzNizszN	NXTa[lY1W0GQR1XS
ACHN	NH[zd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHrZohKSzVyPUCuNFM4OSEQvF2=	MV3TRW5ITVJ?
RH-18	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;6ZWZKSzVyPUCuNFM4PjNizszN	M4HEZ3NCVkeHUh?=
HCC2218	NVzndIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEO3PUDPxE1?	MX;TRW5ITVJ?
OS-RC-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVuwZ4RnUUN3ME2wMlA{QDZ7IN88US=>	MnOwV2FPT0WU
KP-N-YN	NFXrd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDM[lZ{UUN3ME2wMlA{QDd4IN88US=>	NULEUGhpW0GQR1XS
COLO-668	M4n5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17kcGlEPTB;MD6wN\|g5PyEQvF2=	Mn7FV2FPT0WU
LU-65	NELBOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLBTWM2OD1yLkCzPVA1KM7:TR?=	NFrN[I9USU6JRWK=
NB6	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{f2TmlEPTB;MD6wN\|k2OiEQvF2=	MWLTRW5ITVJ?
HT	M3zJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMESwNFch\|ryP	M{PBdnNCVkeHUh?=
COLO-684	NHvibmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMESwPVUh\|ryP	MX;TRW5ITVJ?
NCI-H1693	NX7CNVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml71TWM2OD1yLkC0N\|A2KM7:TR?=	Mn7PV2FPT0WU
LAN-6	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInBb2xKSzVyPUCuNFQ{OzVizszN	NGLBSYxUSU6JRWK=
MDA-MB-175-VII	MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHNdFBxUUN3ME2wMlA1PDF5IN88US=>	NYfn[ZZsW0GQR1XS
KMOE-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2H2emlEPTB;MD6wOFQ3QSEQvF2=	NWf5c4x2W0GQR1XS
DMS-79	NVOwR2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHTcYh1UUN3ME2wMlA1PTd7IN88US=>	NIPkU3hUSU6JRWK=
MHH-NB-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMES2NVQh\|ryP	NXvI[GFQW0GQR1XS
NCI-H69	NWfUTHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PaN2lEPTB;MD6wOFg1QSEQvF2=	M2rhWHNCVkeHUh?=
KE-37	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMEWwNUDPxE1?	M2XvWHNCVkeHUh?=
Ramos-2G6-4C10	M1vFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fY[GlEPTB;MD6wOVA3PyEQvF2=	Mk\lV2FPT0WU
NCI-H1793	M4q4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P5VWlEPTB;MD6wOVA6OyEQvF2=	M4GwPHNCVkeHUh?=
HT-1376	NUD4WGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;lbmlEPTB;MD6wOVE5PiEQvF2=	NWro[G9WW0GQR1XS
EKVX	NITkXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTrbFRXUUN3ME2wMlA2Ozh2IN88US=>	NIrXTYRUSU6JRWK=
Capan-2	NITUb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILteJZKSzVyPUCuNFU{QTZizszN	NID2OGNUSU6JRWK=
DoTc2-4510	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\QPGRVUUN3ME2wMlA2PDR4IN88US=>	MUDTRW5ITVJ?
UACC-893	M{PNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfQSlZKSzVyPUCuNFU1PjJizszN	MYPTRW5ITVJ?
SK-MEL-3	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL0OmN2UUN3ME2wMlA2Pzh6IN88US=>	NF7K[3VUSU6JRWK=
SK-MEL-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP2TWM2OD1yLkC1PEDPxE1?	NVXrcoZMW0GQR1XS
SW948	NGWxTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMEW5PVYh\|ryP	NFLlR4xUSU6JRWK=
P30-OHK	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFKwO4pKSzVyPUCuNFYyPjdizszN	MWTTRW5ITVJ?
NH-12	NH30XItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4njTWlEPTB;MD6wOlI1PCEQvF2=	MkjYV2FPT0WU
KU-19-19	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFL2VJdKSzVyPUCuNFY{PjFizszN	NGXF[I9USU6JRWK=
A431	NVG5ZWdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLjZnpKSzVyPUCuNFY{PzRizszN	MWrTRW5ITVJ?
NCI-H2405	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXvc2RLUUN3ME2wMlA3Ozh\|IN88US=>	MXTTRW5ITVJ?
KARPAS-299	M1Hab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[xRYVKSzVyPUCuNFY2QDJizszN	MnvOV2FPT0WU
BALL-1	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;hb\|lKSzVyPUCuNFY3PzRizszN	NIGzWGhUSU6JRWK=
KURAMOCHI	M4fFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWG2[o5iUUN3ME2wMlA4ODd\|IN88US=>	MW\TRW5ITVJ?
LS-1034	NYHRfHFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf4TWM2OD1yLkC3N\|Y6KM7:TR?=	M4LzbnNCVkeHUh?=
MFE-280	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEe1N\|Yh\|ryP	M3LXd3NCVkeHUh?=
HOP-62	M3n2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEe2O\|Yh\|ryP	M1eyU3NCVkeHUh?=
KG-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEe3PFch\|ryP	MWfTRW5ITVJ?
CW-2	NV\STnBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{X5WGlEPTB;MD6wO\|g{OiEQvF2=	MlvFV2FPT0WU
SW837	NWjPUI8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{e4c2lEPTB;MD6wPFM1OiEQvF2=	NHHxUXhUSU6JRWK=
MFH-ino	NUXKR5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPMTWM2OD1yLkC4OVAyKM7:TR?=	NX3PboNEW0GQR1XS
HCC1419	NGTrXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEi5PFch\|ryP	NEHXZ41USU6JRWK=
HMV-II	NGD3OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[5UGlEPTB;MD6wPVAyKM7:TR?=	NUS1R3ZGW0GQR1XS
BEN	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHKOphHUUN3ME2wMlA6Ozh3IN88US=>	MYXTRW5ITVJ?
SK-N-FI	Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEm1OVYh\|ryP	MlfFV2FPT0WU
JVM-2	M3z0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMEm3NVYh\|ryP	MXHTRW5ITVJ?
CAL-54	NFrmeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXPTWM2OD1yLkGwNFQh\|ryP	MknvV2FPT0WU
T84	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[wTWM2OD1yLkGwPVUzKM7:TR?=	NGnOeHFUSU6JRWK=
SHP-77	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMUG2OFEh\|ryP	MVjTRW5ITVJ?
G-361	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMUKzNlQh\|ryP	MWrTRW5ITVJ?
Calu-3	NEPUVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTqU3MxUUN3ME2wMlE{QDF4IN88US=>	MWfTRW5ITVJ?
HCC1937	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3PV\|JoUUN3ME2wMlE1QTN5IN88US=>	NVHx[2VmW0GQR1XS
KM-H2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjWXXNKSzVyPUCuNVUxOSEQvF2=	M2nYbnNCVkeHUh?=
769-P	M1PoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUn3OIdXUUN3ME2wMlE2QDR\|IN88US=>	NV:5[FExW0GQR1XS
NCI-H1304	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\FTWlEPTB;MD6xOlA3OSEQvF2=	MlLkV2FPT0WU
D-542MG	MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jn[WlEPTB;MD6xOlI4QCEQvF2=	MWPTRW5ITVJ?
ATN-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;2b2pFUUN3ME2wMlE4PDRzIN88US=>	MmrXV2FPT0WU
NCI-H2029	M4ryN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGyeYxlUUN3ME2wMlIxOjR\|IN88US=>	NIHDUXJUSU6JRWK=
ZR-75-30	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i2O2lEPTB;MD6yNFY1OyEQvF2=	MWXTRW5ITVJ?
SW1116	NFrSc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\zNWlEPTB;MD6yNVEyPyEQvF2=	M2PCTHNCVkeHUh?=
CCRF-CEM	M3;6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr6SG9KSzVyPUCuNlc3OTRizszN	M3X2UHNCVkeHUh?=
LU-135	NXm4NFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzjSINKSzVyPUCuNlc4OzlizszN	NFXLUHlUSU6JRWK=
MC116	NXjlfHdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDwTWM2OD1yLkK4N\|A6KM7:TR?=	MnnjV2FPT0WU
LS-513	NU\kVmg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonuTWM2OD1yLkK4O\|c{KM7:TR?=	NEi5fJhUSU6JRWK=
NCI-H630	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMkmzO\|Yh\|ryP	NYG2WW5ZW0GQR1XS
L-428	Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\KTWM2OD1yLkK5PFg{KM7:TR?=	MXjTRW5ITVJ?
UM-UC-3	NFXYN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTNTWM2OD1yLkOxNlkyKM7:TR?=	MXrTRW5ITVJ?
NCI-H1838	M4fOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHKXG9oUUN3ME2wMlMyPzh2IN88US=>	NXzYRoU6W0GQR1XS
HEL	NYXiXoVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDyTWM2OD1yLkOyNlQh\|ryP	NFziVZVUSU6JRWK=
OCI-AML2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ewZ2lEPTB;MD6zNlI6QCEQvF2=	M33v[XNCVkeHUh?=
A3-KAW	NYrNV41kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwM{O0O\|ch\|ryP	NYXFZlI2W0GQR1XS
IGROV-1	NFHScIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvMfplKSzVyPUCuN\|M4PTVizszN	NH;QZlZUSU6JRWK=
Mo-T	NGf6SGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjRXnZKUUN3ME2wMlM{QDV\|IN88US=>	MVjTRW5ITVJ?
HDLM-2	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33VUmlEPTB;MD6zN\|kh\|ryP	M4PTN3NCVkeHUh?=
HCC1569	NIjQSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDhTWM2OD1yLkO0N\|A6KM7:TR?=	MWLTRW5ITVJ?
COLO-678	NUTT[GppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwM{ewNFIh\|ryP	NGniXJJUSU6JRWK=
COR-L105	M{Lyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPiVHg1UUN3ME2wMlM4QTNizszN	NX\5O\|B7W0GQR1XS
SK-MEL-24	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH35V3RKSzVyPUCuN\|g{QDJizszN	NHTDTVVUSU6JRWK=
COLO-320-HSR	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwNEO5O\|Yh\|ryP	NVTPPGtlW0GQR1XS
C8166	NGTyPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwNEmwNlMh\|ryP	NIDiWnBUSU6JRWK=
COLO-679	M2LMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XnVGlEPTB;MD62NlE4OiEQvF2=	NWjoW3NpW0GQR1XS
TE-12	MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPpTllKSzVyPUCuOlU{QTRizszN	Mni2V2FPT0WU
HAL-01	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\uTWM2OD1yLk[2NlIh\|ryP	MlrVV2FPT0WU
H-EMC-SS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwN{C1OFYh\|ryP	NH7vOHhUSU6JRWK=
SNU-449	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnyeYFOUUN3ME2wMlczPzR6IN88US=>	NFqwNmpUSU6JRWK=
C32	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1j1SGlEPTB;MD63OFEyOiEQvF2=	NHHYd5lUSU6JRWK=
K-562	M333[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPy[29WUUN3ME2wMlc4ODJ2IN88US=>	MoTFV2FPT0WU
DJM-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mni4TWM2OD1yLke4O\|gyKM7:TR?=	Moq0V2FPT0WU
RCC10RGB	NFnMTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[2TWM2OD1yLke5NVg{KM7:TR?=	MW\TRW5ITVJ?
CAL-85-1	NXnGcHFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPldVA1UUN3ME2wMlkxPyEQvF2=	NUHRdVZqW0GQR1XS
NY	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwOUOzOVIh\|ryP	M4flNnNCVkeHUh?=
NCI-H1993	NEPDWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTFwMUmyPFkh\|ryP	NFXYPGxUSU6JRWK=
SK-OV-3	NFjrXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTkW\|R2UUN3ME2xMlIzODh7IN88US=>	MXfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PIM1; PubMed: 18426800 J Biol Chem Cells were treated with 100 nm docetaxel for the indicated times. PIM1 and β-ACTIN proteins were analyzed by immunoblot analysis. One of three similar blots is shown. Ratio, ratio of PIM1/β-ACTIN from pooled densitometry data from three separate experimen䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ cyclin B; PubMed: 18426800 J Biol Chem Immunoblot analysis of cyclin B1 and PIM1 expression after docetaxel 10 nm (left) or 100 nm (right) treatment at various time points. pSTAT3 / STAT3 ; PubMed: 18426800 J Biol Chem Immunoblots of RWPE-2 cells treated with 100 nm docetaxel for the indicated time. p-p53 / p53; PubMed: 22996738 Prostate C4-2 cells were treated with 5 nM docetaxel, the whole cell lysates were collected at different time points and subjected to Western blot.	18426800 22996738
Immunofluorescence	α-tubulin; PubMed: 27177833 Exp Cell Res Noscapine has no effect on gross microtubule polymerization state but noscapine pre-sensitization followed by docetaxel treatment stabilizes microtubules, hence inhibits cell proliferation. TNBC cells were treated with noscapine (4 µM) or docetaxel (0.4 µ䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뾠Ղ䐺痖暼瘿뾠Ղᾰƌ 뾠ՂÐ㺣痖뾠Ղ𢡄뾤Ղ䀷痗뾤Ղ౴뾤Ղ㵶痗뾤Ղ뺖᎒泌Itemｾ᎒Count﫨呂뿔Ղ猴፲뾤Ղ፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚Ҕ齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙 cleaved PARP / cleaved caspase-3; PubMed: 21087597 Biochem Pharmacol Immunofluorescence images of PC-3 cells treated with the docetaxel and EM011 schedule treatment. Cells were pretreated with docetaxel for 12 h before addition of EM011 and were fixed at 48 h post docetaxel treatment compared to treatment with EM011 (10 μM䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à Acetylated tubulin ; PubMed: 18426800 J Biol Chem Immunofluorescence of acetylated tubulin in cells treated with DMSO, 30 nM laulimalide and 30 nM docetaxel for 2.5 h. Tubulin shown in green and DAPI in blue, and the white arrow indicates microtubule bundling. Scale bar represents 10 μm. SQSTM1 / LAMP1; PubMed: 29795139 Cell Death Dis AGS cells were treated with docetaxel (10 nM) for 12 h. After immunostaining with SQSTM1 (Alexa Fluor 488, green) and LAMP1 (Alexa Fluor 594, red), cells were examined by fluorescence microscopy (scale bar 20 μm). The colocalization of SQSTM1and LAMP1 was䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ	27177833 21087597 18426800 29795139
Growth inhibition assay	Cell viability ; PubMed: 22996738 Prostate Docetaxel inhibits the growth of LNCaP, C4-2, DU145, and PC3 prostate cancer cells. Cells were plated in 12-well plates and treated with different concentrations of docetaxel. The cell number was counted after 24 hr.	22996738

In vivo

Docetaxel (33 mg/kg/dose, given i.v. every 4 days for 3 injections) results in a tumor growth delay of 19.3 days in M2OL2 colon xenografts. Docetaxel also shows great antitumor activities in MX-1, SK-MEL-2, LX-1 and OVCAR-3 xenografts. Docetaxel inhibits the angiogenic response to fibroblast growth factor 2 with IC 50 of 5.4 mg/kg when injected twice weekly over a 14-day period, and angiogenesis is completely blocked in mice that receives 10 mg/kg Docetaxel. Docetaxel has selectivity for endothelial cell migration and/or microvessel formation because infiltration of inflammatory cells into the Matrigel plug is much less sensitive to inhibition by Docetaxel. ^[7]

Protocol

Cell Research:^[5]

- Collapse

Cell lines: Human gastric cancer cell lines MKN-28
Concentrations: 6 nM
Incubation Time: 3 days
Method: 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO₂. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human colon carcinomas xenografts CX-1
Dosages: 33 mg/kg
Administration: i.v. every 4 days for 3 injections
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (123.78 mM)
	Ethanol	53 mg/mL warmed (65.6 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Docetaxel SDF

Molecular Weight	807.88
Formula	C₄₃H₅₃NO₁₄
CAS No.	114977-28-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RP56976, NSC 628503
Smiles	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04656652	Not yet recruiting	Drug: DS-1062a\|Drug: Docetaxel	Non-small Cell Lung Cancer	Daiichi Sankyo Inc.\|AstraZeneca	December 14 2020	Phase 3
NCT04471675	Not yet recruiting	Drug: Albumin-bound docetaxel	Advanced Solid Tumors	CSPC ZhongQi Pharmaceutical Technology Co. Ltd.	November 15 2020	Phase 1
NCT04396535	Recruiting	Drug: Bintrafusp Alfa\|Drug: Docetaxel	Advanced Lung Non-Small Cell Carcinoma\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	Mayo Clinic\|National Cancer Institute (NCI)	October 23 2020	Phase 2
NCT04533958	Recruiting	Device: HYPNO VR® device	Metastatic Prostate Cancer	Saint-Gregoire Private Hospital Center	September 28 2020	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Paclitaxel

Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Vincristine sulfate

Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Nocodazole

Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin. Vinorelbine Tartrate exhibits anti-tumor activities via inducing the mitotic apoptosis, autophagy and inflammation.
Cabazitaxel

Cabazitaxel (RPR-116258A, XRP6258, TXD 258) is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide. Cabazitaxel induces autophagy via the PI3K/Akt/mTOR pathway.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Docetaxel